Duke-Robert J. Margolis, MD, Institute for Health Policy

09/23/2025

Join us on campus at Duke University next Wednesday, October 1, for "Health Reform and Climate Change: A Duke Climate Collaboration Symposium." Speakers will explore opportunities for health care to reduce its greenhouse gas emissions and implement reforms to mitigate the health impacts of climate change, while simultaneously addressing the challenges of affordability, access, and population health. The event will feature opening remarks from Robert Tighe (Duke University School of Medicine) as well as a keynote address from Bill Frist (The Nature Conservancy and Former Majority Leader, US Senate) and a fireside chat with Duke-Margolis Director Mark McClellan.

Visit the event webpage to register and learn more about session topics and speaker information: https://duke.is/y/s33v

09/18/2025

CMS Administrator Mehmet Oz and Duke-Margolis Director Mark McClellan will discuss CMS' vision and strategies during an upcoming event hosted by The Aspen Institute. Join in-person or virtually next Wednesday, September 24, to learn more! You can register to attend here: https://duke.is/b/49j5

Join us for a lunchtime book talk discussion with David A. Kessler, former Commissioner of the US Food and Drug Administration and co-leader of Operation Warp Speed, in conversation about his New York Times bestseller, Diet, Drugs, and Dopamine: The New Science of Achieving a Healthy Weight

09/16/2025

Join us tomorrow for our next hybrid workshop! Speakers will explore novel efficacy endpoints used in interventional clinical trials for drugs and biological products intended for patients with severe vision loss. A discussion guide is now available—you can read it and register here: https://duke.is/6/jzzn

09/09/2025

The medicines that Americans rely on every day are often products of complex global supply chains, which offer efficiency but also come with vulnerabilities due to geopolitical risks and regulatory challenges. We have released a new white paper to discuss opportunities to improve drug supply chains. This paper provides recommendations for policymakers to pursue international collaborations as a complement to onshoring efforts to achieve a secure, resilient, and efficient supply chain that gets patients the medicines they need. Read more here: https://duke.is/j/pevx

09/08/2025

On October 7, the Duke Center of Global Mental Health is hosting their 2025 conference, "Now More than Ever: Addressing the Global Imperative of Mental Health Equity." They are currently accepting submissions for poster presentations! Registration is free and all are welcome to attend. Learn more and register here: https://sites.duke.edu/dukegmhconf2025/

09/02/2025

Policy Analyst Patrick Rodriguez, Policy Research Associate Nora Emmott, Research Director Rachele Hendricks-Sturrup, and former intern Emma Kikerkov co-authored a paper in the Journal of Pharmacy & Pharmaceutical Sciences that studied pharmacogenomics (PGx) testing data. Health care providers use PGx data, which shows how a patient’s genes interact with certain drugs, to tailor individual treatments. The authors noted that improving racial and genetic ancestry data, and increasing interoperability with electronic health records, could make PGx data more clinically actionable. Read more here: https://duke.is/5/ygcs

Pharmacogenomic (PGx) research investigates how an individual’s genetic make-up impacts their drug metabolism. PGx testing can therefore inform therapeutic d...

08/29/2025

Don't miss your chance to register! Next Wednesday, September 3, we're hosting a workshop with the U.S. Food and Drug Administration to discuss control options in rare disease clinical trials. A final agenda and speaker bios have been posted to the event webpage—you can read them and register here: https://duke.is/z/mkv3

08/22/2025

Speakers have been announced for our upcoming virtual workshop! On September 10, hear from U.S. Food and Drug Administration officials and health policy experts as we discuss challenges and strategies for expedited chemistry, manufacturing, and controls development. Learn more about our speakers and register here: https://duke.is/n/eef3

08/20/2025

Our next event is right around the corner! On September 3, we're hosting a hybrid workshop with the U.S. Food and Drug Administration to explore control options for rare disease clinical trials. Though we have reached capacity for in-person registration, we invite you to join the waitlist or register to attend virtually: https://duke.is/z/mkv3

08/15/2025

A draft agenda is now available for our workshop on September 17, where speakers will discuss clinical trial endpoints for drugs and biological products intended for patients with severe vision loss. Join us at the National Press Club in Washington, DC, to discuss this critical topic and network with your peers. You can read the agenda and register here: https://duke.is/6/jzzn

08/14/2025

Join the U.S. Food and Drug Administration and Duke-Margolis on September 23, 2025, at the National Press Club for a free hybrid meeting on the use of real-world evidence (RWE) in regulatory decision-making. Real-world data and RWE have the potential to help deliver innovative medical products to patients faster and more efficiently, improving overall health outcomes. This public meeting will discuss examples in which RWE was used for regulatory decision-making for medical products. Register today: https://duke.is/y/7nyz

08/12/2025

Hear from Institute Director Mark McClellan at a special edition of the Virtual Value-Based Payment Summit: How to Prepare for the CMS and CMMI Value-Based Care Strategic Initiatives. Mark and his fellow speakers will be discussing the future of Medicare value-based care during the closing fireside chat on September 5. Learn more about the summit, read the agenda, and register here: https://valuebasedpaymentsummit.com/